Hitachi | GenomeWeb

Hitachi

Initial projects include developing new automation systems based on PCR and next-generation sequencing.

Du Pont has been awarded

NEW YORK (GenomeWeb) − One challenge developers of nanopore sequencing technologies have been facing is DNA passing through the pores too quickly to detect its sequence with single-base resolution.

NEW YORK (GenomeWeb) – Annai Systems said today that it is working with Hitachi Data Systems to provide an integrated data management and analysis system that combines Hitachi's high-performance compute and cloud-based solutions and the Annai-GNOS data management software platform.

Title: Method for reconstructing evolutionary data
US Patent Number: 8,645,074
Assignee: International Business Machines

Title: Methods and compositions for base calling nucleic acids
US Patent Number: 8,612,161

NEW YORK (GenomeWeb News) – A group of bioinformatics and technology-focused firms and institutes that challenges informatics researchers to solve specific problems, has issued a new challenge to spur investigators to develop better methods for identifying cancer-associated mutations.

Hitachi High-Technologies has been awarded US Patent No. 8,574,891, "Nucleic acid analyzer, automatic analyzer, and analysis method."
Kohshi Maeda, Masato Ishizawa, Minoru Sano, and Hironori Kaji are named as inventors.

NEW YORK (GenomeWeb News) – The University of California, Santa Cruz said today that Hitachi has sponsored a new cancer genomics research agreement with the university, under which the company will provide research funding and a data storage system that together total over $1 million in support.

Last week, Base4 Innovation said it plans to collaborate with Hitachi to develop a solid-state nanopore sequencer.

Pages

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.